Disruption of Ptk6 significantly delayed and reduced ERBB2-induced mammary gland tumor formation and metastasis, providing strong rationale for therapeutically targeting PTK6 alone or in combination with other agents in ERBB2/HER2-positive breast cancers. Here, ERBB2 is linked to breast carcinoma.